NCT06714903 Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer
| NCT ID | NCT06714903 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Hospital of Jilin University |
| Condition | Colorectal Neoplasms Malignant |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-07-15 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-07-15 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this observational study is to understand the effect of gut microbiota on the efficacy of immunotherapy in patients with metastatic colorectal cancer and to explore the specific mechanisms of this process. In this way, it provides new ideas for the clinical treatment of colorectal cancer.
Eligibility Criteria
Inclusion Criteria: * Clinical and pathological diagnosis of metastatic colorectal cancer * 35-75 years old (both ends inclusive) * complete clinical information * signed informed consent Exclusion Criteria: * combined with severe respiratory and circulatory diseases * combined with other malignant tumors * recent severe active bleeding, uncontrolled active infection or active peptic ulcer * moderate to severe renal insufficiency * other circumstances that are judged by the investigator to be unsuitable for participating in this study
Contact & Investigator
Nan Zhang
STUDY DIRECTOR
The First Hospital of Jilin University
Frequently Asked Questions
Who can join the NCT06714903 clinical trial?
This trial is open to participants of all sexes, aged 35 Years or older, up to 75 Years, studying Colorectal Neoplasms Malignant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06714903 currently recruiting?
Yes, NCT06714903 is actively recruiting participants. Contact the research team at zhangnan@jlu.edu.cn for enrollment information.
Where is the NCT06714903 trial being conducted?
This trial is being conducted at Changchun, China.
Who is sponsoring the NCT06714903 clinical trial?
NCT06714903 is sponsored by The First Hospital of Jilin University. The principal investigator is Nan Zhang at The First Hospital of Jilin University. The trial plans to enroll 50 participants.